Home / Cancer treatment in China / Colorectal cancer treatment

Stage is one input

Colorectal Cancer Treatment by Stage

Stage changes which tools are usually discussed. It does not, by itself, choose the treatment. Localized and Stage I disease are often surgical questions. Stage II and Stage III add chemotherapy, and rectal cancer often adds radiation or chemoradiation because the pelvis is different from the colon. Regional nodes change risk. Stage IV means distant spread. Some liver or lung lesions can be removed, and some unresectable disease is treated first to see if surgery becomes possible. Biomarkers still apply whenever a drug is considered.

Applicability: Stage II colon cancer and Stage II rectal cancer are not the same conversation. Nodes, margins, and markers still move the plan.

Review my case
LocalizedRegionalStage IV is not one disease

Localized disease

A tumor that has not spread beyond the bowel is often treated with surgery. Endoscopic removal can be enough for some very early polyps and cancers. That decision belongs to the endoscopist and the pathology, not to a stage label alone.

Stage I

Stage I is usually a surgical question if the cancer was not already removed completely as a polyp. Routine chemotherapy is not the default story. Rectal Stage I can still raise a radiation or organ-preservation question that colon Stage I usually does not.

Stage II

Stage II means the tumor is deeper or involves nearby tissue without the regional nodes that define Stage III. Chemotherapy is a risk discussion, not an automatic order. High-risk features, the rectal site, and MSI or MMR status change that discussion. MSI-H or dMMR Stage II colon cancer is a known setting where chemotherapy may be less useful. That sentence is not a rule for rectal cancer or for Stage III.

Stage III and regional nodes

Regional means the nearby lymph nodes are involved. Surgery plus chemotherapy is the usual colon-cancer frame. Rectal cancer in this range usually brings radiation or chemoradiation into the sequence, sometimes before surgery, and sometimes with a watch-and-wait discussion after a complete clinical response. A 2026 CSCO interpretation adds FOLFOX plus atezolizumab as an adjuvant option for stage III dMMR colon cancer. That is a guideline sentence for one biomarker group. It is not an approval claim on this page, and it is not a plan for MSS or pMMR disease. Node status raises risk. It does not name the drug.

Stage IV

Stage IV means distant metastases. Some of those cases are still treated with surgery on the bowel and on the liver or lung. Some are not resectable at diagnosis and are treated systemically first. The metastatic page holds that decision. Calling every Stage IV case palliative is too coarse, and calling every Stage IV case curable is also too coarse.

Why stage is not enough

The same five facts come before a drug name: colon or rectum, stage, whether the disease can be removed, where any metastases are, and prior treatment. The markers that change drug choice are RAS and NRAS, BRAF, MSI or MMR, and HER2 when that test was done. Other actionable findings are read the same way. Patient fitness still matters. One of those facts is not a plan.

In this cluster

Technology pages already on this site, used only when a case actually needs them: proton therapy, microwave ablation, cryoablation, and interventional oncology. None of those replaces surgery or systemic therapy for colorectal cancer as a default.

Questions people ask

How is colorectal cancer treated by stage?

Localized and Stage I disease are often surgical. Stage II adds a chemotherapy decision that depends on risk, site, and MSI or MMR. Stage III usually adds chemotherapy, and rectal cancer often adds radiation. Stage IV is metastatic disease: some metastases can be removed, and some cannot. Stage alone does not pick the regimen.

Sources

  • NCI, Colon Cancer Treatment (PDQ) patient version. Used for the general distinction between colon treatment and a personal plan.
  • NCI, Rectal Cancer Treatment (PDQ) patient version. Used for the point that rectal cancer more often involves radiation than colon cancer.
  • National Health Commission colorectal cancer specification, 2025 edition. English summary: Chin J Cancer Res 2025;37(6):949-961. doi 10.21147/j.issn.1000-9604.2025.06.07. This is a practice framework, not a 2026 drug list.
  • CSCO colorectal guideline version 2026, as interpreted in Chin J Cancer Res 2026;38(3):329-335. doi 10.21147/j.issn.1000-9604.2026.03.10. The full guideline PDF was not pasted here.
  • Cao and Jiang, 1 October 2026. Digestive Oncology, electronic edition, 2026;18(3):358-363. Used for the metastatic nivolumab sentence, the stage III dMMR adjuvant sentence, and the first-line BRAF move.

Last reviewed: 3 October 2026. A trial permission, a guideline sentence, and a drug label are three different documents.

Check whether stage is the whole question

A stage number is not a drug list. ParkMega does not assign stage or choose treatment.

Message us on WhatsApp without this form